SCHEMBL4049351

SCHEMBL4049351

CCCCOC(=O)N1CCCC1=O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.47
SMN1; SMN2 Q16637 3/20 0.46
POLB P06746 2/20 0.46
KMT2A Q03164 5/20 0.43
MAPT P10636 2/20 0.43
MEN1 O00255 2/20 0.43
KDM4E B2RXH2 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2D6 P10635 1/20 0.43
THRB P10828 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
RECQL P46063 1/20 0.43
BLM P54132 1/20 0.43
ALDH1A1 P00352 2/20 0.40
RAB9A P51151 2/20 0.39
TDP1 Q9NUW8 3/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
CASP6 P55212 1/20 0.39
BCHE P06276 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2785830 0.95 SMN1; SMN2 (0.45) LMNASMN1; SMN2POLBKMT2AMAPT
SCHEMBL977716 0.94 LMNA (0.45) LMNASMN1; SMN2POLBALDH1A1GBA2
SCHEMBL10494935 0.94 LMNA (0.45) LMNASMN1; SMN2POLBALDH1A1GBA2
SCHEMBL10494999 0.94 LMNA (0.45) LMNASMN1; SMN2POLBALDH1A1GBA2
SCHEMBL10494937 0.94 LMNA (0.45) LMNASMN1; SMN2POLBALDH1A1GBA2
SCHEMBL10494979 0.94 LMNA (0.45) LMNASMN1; SMN2POLBALDH1A1GBA2
SCHEMBL10494965 0.94 LMNA (0.45) LMNASMN1; SMN2POLBALDH1A1GBA2
SCHEMBL10494901 0.94 LMNA (0.45) LMNASMN1; SMN2POLBALDH1A1GBA2
SCHEMBL10494940 0.94 LMNA (0.45) LMNASMN1; SMN2POLBALDH1A1GBA2
SCHEMBL10494980 0.94 LMNA (0.45) LMNASMN1; SMN2POLBALDH1A1GBA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113493628-A Quantum dot ink and preparation method of quantum dot film TCL科技集团股份有限公司 2021-10-12 CN claimed
CN-110582493-B Benzoxazole derivatives as immunomodulators 因赛特公司 2024-03-08 CN disclosed
CN-113493628-A Quantum dot ink and preparation method of quantum dot film TCL科技集团股份有限公司 2021-10-12 CN disclosed
WO-2014042939-A1 KETONE LINKED BENZOTHIAZOLE INHIBITORS OF ENDOTHELIAL LIPASE BRISTOL-MYERS SQUIBB COMPANY (US) 2014-03-20 WO disclosed
WO-2009033079-A1 EXTERNALLY MASKED NEOPENTYL SULFONYL ESTER CYCLIZATION RELEASE PRODRUGS OF ACAMPROSATE, COMPOSITIONS THEREOF, AND METHODS OF USE XENOPORT, INC. (US) 2009-03-12 WO disclosed
US-6927222-B2 1,3,4,5-tetrahydro-pyrido(4,3-b)indole-2-yl derivative useful for treating rheumatoid arthritis, chronic obstructive pulmonary disease, asthma and multple sclerosis ASTRAZENECA AB (SE) 2005-08-09 US disclosed
EP-1325146-A2 PROCESS FOR PREPARING OPTICALLY ACTIVE 4-HYDROXY-2-PYRROLIDINONE AND N-SUBSTITUTED 4-HYDROXY-2-PYRROLIDINONES BY ENZYMATIC HYDROXYLATION Eidgenössiche Technische Hochschule Zürich (CH) 2003-07-09 EP disclosed
EP-1263725-A1 NOVEL COMPOUNDS AstraZeneca AB (SE) 2002-12-11 EP disclosed
EP-1263760-A1 NOVEL COMPOUNDS AstraZeneca AB (SE) 2002-12-11 EP disclosed
WO-2002031174-A2 PROCESS FOR PREPARING OPTICALLY ACTIVE 4-HYDROXY-2-PYRROLIDINONE AND N-SUBSTITUTED 4-HYDROXY-2-PYRROLIDINONES BY ENZYMATIC HYDROXYLATION EIDGENÖSSICHE TECHNISCHE HOCHSCHULE ZÜRICH (CH) 2002-04-18 WO disclosed
WO-2001062757-A1 NOVEL COMPOUNDS ASTRAZENECA AB (SE) 2001-08-30 WO disclosed
WO-2001062729-A1 NOVEL COMPOUNDS ASTRAZENECA AB (SE) 2001-08-30 WO disclosed
US-4863952-A Method of promoting percutaneous drug absorption with 2-pyrrolidin-2-one 5-carboxylic acids and esters thereof NITTO ELECTRIC INDUSTRIAL CO., LTD. (JP) 1989-09-05 US disclosed